Search bioRxiv⌕ Search

Biology subjects

Khamas, A. B.

Publications and source records attributed to Khamas, A. B..

3 recordsLinked to original sources

The host environment activates multiple stress responses which correlate with antibiotic tolerance in Staphylococcus aureus

Introduction. Antibiotic tolerance allows genetically susceptible bacteria to survive antibiotic exposure and contributes to treatment failure and recurrent infection. In Staphylococcus aureus, tolerance is closely associated with biofilm infections, and this association is conventionally explained by the biofilm mode of growth itself, in which mass transfer limitation is presumed to starve and arrest cells in the deeper layers. Gap Statement. That explanation rests largely on biofilms grown in rich laboratory media, and it has rarely been tested against the alternative that the host environment, rather than the biofilm architecture, drives the underlying physiological change. Furthermore, because transcriptomic and bulk fluorescence methods average across the population, they cannot establish whether stress responses are activated uniformly in all cells or strongly in a minority. Aim. To determine, at single-cell resolution, whether bacterial stress responses are activated by biofilm growth, by the host environment, or by both, and whether such activation coincides with a reduced rate of antibiotic killing. Methodology. Promoter regions of recA, katA, relQ, ilvleu and groESL were fused to a stable green fluorescent protein variant to report the SOS, oxidative stress, cell wall stress- and starvation-activated stringent, and heat shock responses. Reporter activation was quantified by confocal microscopy in exponential and stationary cultures, after defined chemical and physical stresses, in biofilms grown in tryptic soy broth, in diluted and undiluted human serum, in heat-inactivated serum, and in S. aureus internalised by human neutrophils. Tolerance was assessed as the rate of killing in time-kill assays. Results. Biofilms grown in laboratory media or in diluted serum showed minimal stress response activation, whereas biofilms of the same strain grown in undiluted human serum activated all five responses, uniformly across the population. Heat inactivation of the serum did not abolish this effect, indicating that complement and heat-labile serum enzymes are not required. One hour of serum exposure activated the stringent response via both starvation and cell wall stress, and it abolished detectable killing by ciprofloxacin, while producing only small changes in killing by vancomycin and rifampicin and none by daptomycin or dicloxacillin. Pre-treatments that activated the stringent or heat shock responses likewise arrested growth and slowed ciprofloxacin killing. Neutrophil phagocytosis activated the oxidative stress response and both stringent response branches. The host environment, rather than the biofilm mode of growth, is the dominant driver of stress response activation in S. aureus. Activation is population-wide and coincides with population-wide ciprofloxacin tolerance. Laboratory biofilm models that omit host components are therefore likely to underestimate the tolerance encountered during infection.

microbiology↗

Mitomycin C Retains Efficacy after Adaptive Laboratory Evolution of Staphylococcus aureus

Antibiotic resistance is one of the greatest threats against human health and the misuse and overuse of antibiotics is a key factor driving resistance development. During prolonged antibiotic treatment of chronic infections, the antimicrobial pressure facilitates selection of antibiotic resistance mutations. It has been suggested that using antibiotics in combinations may reduce the emergence of resistance. Furthermore, antibiotic tolerant persister cells may be a reservoir for resistance development, so targeting persister cells with anti-persister drugs could also reduce the emergence of resistance. In this study, we conducted a 42-day adaptive laboratory evolution experiment using Staphylococcus aureus exposed to common antibiotics and the anti-persister drug mitomycin C, either alone or in combination. We monitored susceptibility daily and assessed phenotypic changes in growth and biofilm formation in evolved strains. Whole-genome sequencing revealed mutations linked to antibiotic resistance and phenotypic shifts. Resistance developed rapidly against rifampicin, while ciprofloxacin and daptomycin showed slower resistance emergence. Treatments with vancomycin or mitomycin C resulted in minimal changes in susceptibility. Combination therapies generally delayed resistance, though resistance was not fully prevented. Notably, mitomycin C combined with rifampicin effectively suppressed rifampicin resistance. Sub-inhibitory antibiotic concentrations were associated with both known and novel mutations, including in the nucleotide excision repair system and azoreductase, following mitomycin C treatment--mutations not previously reported. While combination therapy delayed resistance, mitomycin Cs efficacy and ability to prevent rifampicin resistance highlights its potential in combating antibiotic resistance. Further investigation is needed to evaluate the broader application of anti-persister drugs in resistance prevention.

microbiology↗

Antibody-drug conjugates to treat bacterial biofilms

Implant-associated infections remain a grand unmet medical need because they involve biofilms that protect bacteria from the immune system and harbour antibiotic-tolerant persister cells. There is an urgent need for new biofilm-targeting therapies with antimicrobials, to treat these infections via a non-surgical way. In this work, we address this urgent medical need and engineer antibody-drug conjugates (ADC) that kill bacteria in suspension and in biofilms, in vitro and in vivo. The ADC contains an anti-neoplastic drug mitomycin C, which is also a potent antimicrobial against biofilms. While most ADCs are clinically validated as anti-cancer therapeutics where the drug is released after internalisation of the ADC in the target cell, the ADCs designed herein release the conjugated drug without cell entry. This is achieved with a novel mechanism of drug, which likely involves an interaction of ADC with thiols on the bacterial cell surface. ADC targeted towards bacteria were superior by the afforded antimicrobial effects compared to the non-specific counterpart, in suspension and within biofilms, in vitro and in vivo. An implant-associated murine osteomyelitis model was then used to demonstrate the ability of the antibody to reach the infection, and the superior antimicrobial efficacy compared to standard antibiotic treatment in vivo. Our results illustrate the development of ADCs into a new area of application with a significant translational potential.

microbiology↗